|Bid||0.00 x 1200|
|Ask||81.00 x 800|
|Day's Range||79.77 - 80.86|
|52 Week Range||52.83 - 80.86|
|Beta (3Y Monthly)||0.38|
|PE Ratio (TTM)||34.81|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.20 (2.78%)|
|1y Target Est||83.02|
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 95,953 shares of MRK on 02/22/2019 at an average price of $80.01 a share.
Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.
Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
NEW YORK , Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning ...
NEW YORK, Feb. 21, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Immune Design Corp. (“Immune Design”.
Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...
Merck's (MRK) sBLA looking for approval of Keytruda monotherapy for the third-line treatment of small cell lung cancer, a difficult-to-treat cancer, gets FDA's priority review.
SAN DIEGO , Feb. 21, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immune Design Corp. (NASDAQ: IMDZ) ("Immune ...
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
In a collaboration announced Tuesday, Keytruda will be tested with Torque's T-cell therapy against several cancers.
shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration. Merck said late Tuesday that its Keytruda treatment for patients with advanced liver cancer who were previously treated with systemic therapy did not meet the endpoints for overall survival when compared with placebo plus best supportive care. "While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings from the Phase 2 study, which led to the accelerated approval of KEYTRUDA for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib," said chief medical officer Dr. Roy Baynes.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Marks First Application for KEYTRUDA in SCLC
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 135,613 shares of MRK on 02/19/2019 at an average price of $80.03 a share.
Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main goals of slowing disease progression and extending the life of patients with a common type of liver cancer, the company said on Tuesday. The results could hamper prospects for the drug, which had received an accelerated approval from the U.S. Food and Drug Administration in November as a treatment for patients with advanced liver cancer who had been previously treated with Bayer AG's Nexavar. Keytruda, which is approved to treat several forms of cancer including skin and lung cancer, is Merck's biggest drug and brought in revenue of $7.17 billion last year.
Merck & Co. Inc. shares declined in after-hours trading Tuesday after the company announced that a study of its Keytruda drug did not meet its goals. The company said that a study on the effectiveness of the drug for patients with a specific type of liver cancer did not reach its defined goals for survival. Merck is testing the drug on a variety of cancers in a big bet on immunotherapy for cancer. Merck shares dipped slightly more than 1% in the extended session after making the announcement, following a 0.7% decline in the regular session. The stock has gained 40.8% in the past 12 months as the S&P 500 index has gained 1.6%.
Merck , known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus best supportive care, for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy, did not meet its co-primary endpoints of overall survival and progression-free survival ...